Novynette 21 tablets & 63 tablets Contraception Новинет

Novunette Indications

Contraception

Dosage & Administration

The usage is started with the 1st day of the menstrual cycle and take 1 tablet a day for 21 days, if possible at one and the same time of day. After taking the last pill make 7-day break, during which there menstrualnopodobnoe bleeding as a result of drug withdrawal. On the next day after a 7-day interval (after 4 weeks after the first pill in the same day of the week) resuming reception of the next package that contains a tablet 21, even if the bleeding has stopped. Thus tablets continue to take as long as there is a need for contraception. Subject to the rules receive the contraceptive effect of the drug persists for the duration of the 7-day break.
First taking the drug
The first tablet should be taken in the 1st day of the menstrual cycle. In this case, additional methods of contraception are not required.
Receiving tablets can be started with 2-5 and the first day of menstruation, but in this case in the first cycle should be applied additional methods of contraception during the first 7 days of taking the pills. If it has been more than 5 days from the onset of menstruation, it is necessary to postpone the start of reception until the next menstrual period.
Taking the drug after a child birth
Women who do not breastfeed, you should start taking the tablets 21 days after birth. In this case, there is no need to use other methods of contraception.
If after delivery has been sexual intercourse, the drug should be postponed until the next menstrual period.
If a woman makes a decision on the admission of the drug later than 21 days after giving birth, in the first 7 days is necessary to use additional methods of contraception.
Taking the drug after an abortion
The drug should be started from the 1st day after the abortion, in this case there is no need to use additional methods of contraception.

Contradictions

Absolute contraindications: pregnancy or suspected it, AG moderate or severe, lipid metabolism, the presence or indication of a history of arterial thromboembolic disease (myocardial infarction, ischemic stroke), the risk of arterial or venous thromboembolism, the presence of venous thromboembolism in a personal or family history of diabetic angiopathy, or an indication of the presence of a history of severe liver disease, cholestatic jaundice, hepatitis, jaundice during pregnancy, when the use of steroids, the syndrome of Dubin - Johnson syndrome or rotor, in tumors of the liver, porphyria;

hepatitis B (over 3 months since the normalization of laboratory parameters), gallstone disease, the presence of estrogen-dependent tumors or suspicion on them, endometrial hyperplasia, genital bleeding of unknown etiology.